Document:

EXHIBIT 10.8
                                                                    ------------

                                                                  EXECUTION COPY

THIS DEBENTURE, AND THE SECURITIES INTO WHICH IT IS CONVERTIBLE (COLLECTIVELY,
THE "SECURITIES"), HAVE NOT BEEN REGISTERED WITH THE UNITED STATES SECURITIES
AND EXCHANGE COMMISSION (THE "COMMISSION") OR THE SECURITIES COMMISSION OF ANY
STATE. THE SECURITIES ARE BEING OFFERED PURSUANT TO A SAFE HARBOR FROM
REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"). THE
SECURITIES ARE "RESTRICTED" AND MAY NOT BE OFFERED OR SOLD UNLESS THE SECURITIES
ARE REGISTERED UNDER THE ACT PURSUANT TO AVAILABLE EXEMPTIONS FROM THE
REGISTRATION REQUIREMENTS OF THE ACT AND THE COMPANY WILL BE PROVIDED WITH
OPINION OF COUNSEL OR OTHER SUCH INFORMATION AS IT MAY REASONABLY REQUIRE TO
CONFIRM THAT SUCH EXEMPTIONS ARE AVAILABLE. FURTHER HEDGING TRANSACTIONS
INVOLVING THE SECURITIES MAY NOT BE MADE EXCEPT IN COMPLIANCE WITH THE ACT.

                                    DEBENTURE

                          THOMAS PHARMACEUTICALS, LTD.

                        (f/k/a iVoice Acquisition Corp.)

                  Administrative Service Convertible Debenture

                               Due January 1, 2013

No. 2A                                                                  $100,000

     This Debenture is issued by Thomas Pharmaceuticals, Ltd. (f/k/a iVoice
Acquisition Corp.), a New Jersey corporation with its principal office located
at 750 Route 34, Matawan, NJ, 07747 (the "Company"), to iVoice, Inc., a New
Jersey Corporation, with its principal office at 750 Route 34, Matawan, NJ,
07747 (together with its permitted successors and assigns, the "Holder")
pursuant to exemptions from registration under the Act.

                                   ARTICLE I.

     Section 1.01 Principal and Interest. For value received, on January 6,
2006, the Company hereby promises to pay to the order of the Holder in lawful
money of the United States of America and in immediately available funds the
principal sum of One Hundred Thousand Dollars (US $100,000) on January 1, 2013
(the "Maturity Date"), together with interest, compounded quarterly, on the
unpaid principal of this Debenture at the rate of ten percent (10%) per year
(computed on the basis of a 365-day year and the actual days elapsed) from the
date of this Debenture until paid.

     Section 1.02 Optional Conversion. The Holder is entitled, at its option, to
convert, and sell on the same day, at any time and from time to time, until
payment in full of this

<PAGE>

Debenture, all or any part of the principal amount of the Debenture, plus
accrued interest, into shares (the "Conversion Shares") of the Company's common
stock, par value $0.0001 per share ("Common Stock"), at the price per share (the
"Conversion Price") equal to an amount equal to eighty percent (80%) of the
lowest closing bid price of the Common Stock for the five (5) trading days
immediately preceding the Conversion Date (as defined herein). This is the
"Conversion Price".

     As used herein, "Principal Market" shall mean The National Association of
Securities Dealers Inc.'s Over-The-Counter Bulletin Board, Nasdaq SmallCap
Market, or American Stock Exchange. If the Common Stock is not traded on a
Principal Market, the Closing Bid Price shall mean, the reported closing bid
price for the Common Stock, as furnished by the National Association of
Securities Dealers, Inc., for the applicable periods. No fraction of shares or
scrip representing fractions of shares will be issued on conversion, but the
number of shares issuable shall be rounded to the nearest whole share. To
convert this Debenture, the Holder hereof shall deliver written notice thereof,
substantially in the form of Exhibit "A" to this Debenture, with appropriate
insertions (the "Conversion Notice"), to the Company at its address as set forth
herein. The date upon which the conversion shall be effective (the "Conversion
Date") shall be deemed to be the date set forth in the Conversion Notice.

     Section 1.03 Reservation of Common Stock. The Company shall reserve and
keep available out of its authorized but unissued shares of Common Stock, solely
for the purpose of effecting the conversion of this Debenture, such number of
shares of Common Stock as shall from time to time be sufficient to effect such
conversion, based upon the Conversion Price; provided, however, until such time
as the Conversion Price has been fixed, but solely for the purposes of this
Section 1.03 only, the Conversion Price shall be deemed to be $0.002 or, if
there is a trading market for the Common Stock, the lowest bid price for the
preceding thirty (30) days. If at any time the Company does not have a
sufficient number of Conversion Shares authorized and available, then the
Company shall call and hold a special meeting of its stockholders within sixty
(60) days of that time for the sole purpose of increasing the number of
authorized shares of Common Stock.

     Section 1.04 Right of Redemption. The Company at its option shall have the
right to redeem, with thirty (30) business days advance written notice (the
"Redemption Notice"), a portion of or all of the outstanding principal sum under
this Debenture. The redemption price shall be equal to one hundred twenty-five
percent (125%) multiplied by the portion of the principal sum being redeemed,
plus any accrued and unpaid interest. Once the Company has issued to the Holder
a Redemption Notice, the Holder may continue to convert this Debenture, in
accordance with Section 1.02 hereof, for the thirty (30) day business period
after the Holder receives the Redemption Notice.

     Section 1.05 Registration Rights. The Company is obligated to register the
resale of the Conversion Shares under the Securities Act of 1933, as amended,
pursuant to the terms of a Shareholders Agreement, between the Company and the
Holder of even date herewith (the "Shareholders Agreement").

     Section 1.06 Guaranty. Upon the occurrence of an Event of Default (as
defined in Article III hereto), this Convertible Debenture shall be immediately
due and payable.

                                        2
<PAGE>

     Section 1.07 Interest Payments. The interest so payable will be paid at the
time of maturity or conversion to the person or company in whose name this
Debenture is registered. At the time such interest is payable, the Company, in
its sole discretion, may elect to pay interest in cash (via wire transfer or
certified funds) or in the form of Common Stock. In the event of default, as
described in Article III hereunder, the Holder may elect that the interest be
paid in cash (via wire transfer or certified funds) or in the form of Common
Stock. If paid in the form of Common Stock, the amount of stock to be issued
will be calculated as follows: the value of the stock shall be the closing bid
price on: (i) the date the interest payment is due; or (ii) if the interest
payment is not made when due, the date the interest payment is made. A number of
shares of Common Stock with a value equal to the amount of interest due shall be
issued. No fractional shares will be issued; therefore, in the event that the
value of the Common Stock per share does not equal the total interest due, the
Company will pay the balance in cash.

     Section 1.08 Paying Agent and Registrar. Initially, the Company will act as
paying agent and registrar. The Company may change any paying agent, registrar,
or Company-registrar by giving the Holder not less than ten (10) business days'
written notice of its election to do so, specifying the name, address, telephone
number and facsimile number of the paying agent or registrar.

                                   ARTICLE II.

     Section 2.01 Amendments and Waiver of Default. The Debenture may not be
amended without the consent of the Holder. Notwithstanding the above, without
the consent of the Holder, the Debenture may be amended to cure any ambiguity,
defect or inconsistency, to provide for assumption of the Company obligations to
the Holder or to make any change that does not adversely affect the rights of
the Holder.

                                  ARTICLE III.

     Section 3.01 Events of Default. An "Event of Default", wherever used
herein, means any one of the following events (whatever the reason and whether
it shall be voluntary or involuntary or effected by operation of law or pursuant
to any judgment, decree or order of any court, or any order, rule or regulation
of any administrative or governmental body):

     (i) Any default in the payment of the principal of, interest on or other
     charges in respect of this Debenture, free of any claim of subordination,
     as and when the same shall become due and payable and that is not cured
     within ten (10) days of the Company's receipt of written notice from the
     Holder explaining such default in reasonable detail (whether on an
     installment, a Principal Payment Date, an Interest Payment Date, a
     Conversion Date or the Maturity Date or by acceleration or otherwise);

     (ii) The Company shall fail to observe or perform any other covenant,
     agreement or warranty contained in, or otherwise commit any breach or
     default of any provision of this Debenture hereof or the Shareholders
     Agreement, Security Agreement, or the Escrow Agreement which is not cured
     with in the time prescribed;

     (iii) The Company or any subsidiary of the Company shall commence, or there
     shall be commenced against the Company or any subsidiary of the Company
     under any applicable bankruptcy or insolvency laws as now or hereafter in
     effect or any successor thereto, or the Company or any subsidiary of the
     Company commences any other proceeding under any

                                        3
<PAGE>

     reorganization, arrangement, adjustment of debt, relief of debtors,
     dissolution, insolvency or liquidation or similar law of any jurisdiction
     whether now or hereafter in effect relating to the Company or any
     subsidiary of the Company or there is commenced against the Company or any
     subsidiary of the Company any such bankruptcy, insolvency or other
     proceeding which remains undismissed for a period of sixty one (61) days;
     or the Company or any subsidiary of the Company is adjudicated insolvent or
     bankrupt; or any order of relief or other order approving any such case or
     proceeding is entered; or the Company or any subsidiary of the Company
     suffers any appointment of any custodian, private or court appointed
     receiver or the like for it or any substantial part of its property which
     continues undischarged or unstayed for a period of sixty one (61) days; or
     the Company or any subsidiary of the Company makes a general assignment for
     the benefit of creditors; or the Company or any subsidiary of the Company
     shall fail to pay, or shall state that it is unable to pay, or shall be
     unable to pay, its debts generally as they become due; or the Company or
     any subsidiary of the Company shall call a meeting of its creditors with a
     view to arranging a composition, adjustment or restructuring of its debts;
     or the Company or any subsidiary of the Company shall by any act or failure
     to act expressly indicate its consent to, approval of or acquiescence in
     any of the foregoing; or any corporate or other action is taken by the
     Company or any subsidiary of the Company for the purpose of effecting any
     of the foregoing;

     (iv) The Company or any subsidiary of the Company shall default in any of
     its obligations under any other debenture or any mortgage, credit agreement
     or other facility, indenture agreement, factoring agreement or other
     instrument under which there may be issued, or by which there may be
     secured or evidenced any indebtedness for borrowed money or money due under
     any long term leasing or factoring arrangement of the Company or any
     subsidiary of the Company in an amount exceeding $20,000, whether such
     indebtedness now exists or shall hereafter be created and such default
     shall result in such indebtedness becoming or being declared due and
     payable prior to the date on which it would otherwise become due and
     payable;

     (v) At any time following the time the Company has been quoted for trading
     or listed for trading on the Nasdaq OTC Bulletin Board ("OTC"), Nasdaq
     SmallCap Market, New York Stock Exchange, American Stock Exchange or the
     Nasdaq National Market (each, a "Subsequent Market"), the Common Stock
     shall cease to be so quoted for trading or listed for trading on a
     Subsequent Market") and shall not again be quoted or listed for trading
     thereon within five (5) trading days of such delisting;

     (vi) The Company shall fail to file the Initial Registration Statement with
     the Commission (as defined in Section 2(a) of the Investor Registration
     Rights Agreement), or the Initial Registration Statement shall not have
     been declared effective by the Commission, in each case within the time
     periods set forth in the Investor Registration Rights Agreement of even
     date herewith between the Company and the Holder;

                                        4
<PAGE>

     (vii) If the effectiveness of the Initial Registration Statement lapses for
     any reason or the Holder shall not be permitted to resell the shares of
     Common Stock underlying this Debenture under the Initial Registration
     Statement, in either case, for more than five (5) consecutive trading days
     or an aggregate of eight trading days (which need not be consecutive
     trading days);

     (viii) The Company shall fail for any reason to deliver Common Stock
     certificates to a Holder prior to the fifth (5th) trading day after a
     Conversion Date or the Company shall provide notice to the Holder,
     including by way of public announcement, at any time, of its intention not
     to comply with requests for conversions of this Debenture in accordance
     with the terms hereof;

     Section 3.02 Payment on Event of Default. During the time that any portion
of this Debenture is outstanding, if any Event of Default has occurred, the full
principal amount of this Debenture, together with interest and other amounts
owing in respect thereof, to the date of acceleration shall become at the
Holder's election, immediately due and payable in cash, provided however, the
Holder may request (but shall have no obligation to request) payment of such
amounts in Common Stock of the Company. Upon the occurrence of an Event of
Default, the Holder may, in its sole discretion, accelerate full repayment of
all debentures outstanding and accrued interest thereon or may convert all
debentures outstanding and held by Holder and accrued interest thereon into
shares of Common Stock at a conversion price equal to the lowest quoted Bid
price of the Company's Common Stock, as quoted by Bloomberg, LP, for the first
five (5) trading days after the Company's Common Stock becomes listed on the OTC
Bulletin Board. The Holder need not provide and the Company hereby waives any
presentment, demand, protest or other notice of any kind, and the Holder may
immediately and without expiration of any grace period enforce any and all of
its rights and remedies hereunder and all other remedies available to it under
applicable law. Such declaration may be rescinded and annulled by Holder at any
time prior to payment hereunder. No such rescission or annulment shall affect
any subsequent Event of Default or impair any right consequent thereon. Upon an
Event of Default, notwithstanding any other provision of this Debenture, the
Holder shall have no obligation to the Company comply with or adhere to any
limitations, if any, on the conversion of this Debenture or the sale of the
Conversion Shares.

     Section 3.03 Failure to Issue Unrestricted Common Stock. As indicated in
Article III Section 3.01, a breach by the Company of its obligations under the
Shareholders Agreement shall be deemed an Event of Default, which if not cured
within ten (10) days, shall entitle the Holder accelerated full repayment of all
debentures outstanding and held by Holder. The Company acknowledges that failure
to honor a Notice of Conversion shall cause irreparable harm to the Holder.

                                   ARTICLE IV.

     Section 4.01 Rights and Terms of Conversion. This Debenture, in whole or in
part, may be converted at any time following the date of closing, into shares of
Common Stock at a price equal to the Conversion Price as described in Section
1.02 above.

                                        5
<PAGE>

     Section 4.02 Re-issuance of Debenture. When the Holder elects to convert a
part of the Debenture, then the Company shall reissue a new Debenture in the
same form as this Debenture to reflect the new principal amount.

                                   ARTICLE V.

     Section 5.01 Anti-dilution. In the event that the Company shall at any time
subdivide the outstanding shares of Common Stock, or shall issue a stock
dividend on the outstanding Common Stock, the Conversion Price in effect
immediately prior to such subdivision or the issuance of such dividend shall be
proportionately decreased, and in the event that the Company shall at any time
combine the outstanding shares of Common Stock, the Conversion Price in effect
immediately prior to such combination shall be proportionately increased,
effective at the close of business on the date of such subdivision, dividend or
combination as the case may be.

     Section 5.02 Consent of Holder to Sell Common Stock. If at any time the
Holder does not control a majority of the voting securities of the Company and
so long as any of the principal of or interest on this Note remains unpaid and
unconverted, the Company shall not, without the prior consent of the Holder,
issue or sell (i) any Common Stock without consideration or for a consideration
per share less than its fair market value determined immediately prior to its
issuance, (ii) issue or sell any warrant, option, right, contract, call, or
other security or instrument granting the holder thereof the right to acquire
Common Stock without consideration or for a consideration per share less than
such Common Stock's fair market value determined immediately prior to its
issuance, or (iii) file any registration statement on Form S-8. Holder shall
take no action, without the consent of the holders of a majority of the
Company's Series A Preferred Stock (or the Common Stock that the Series A
Preferred Stock is converted into), that would cause a breach of this Section
5.02.

                                  ARTICLE VI.

     Section 6.01 Notice. All notices or other communications required or
permitted to be given pursuant to this Debenture shall be in writing and shall
be considered as duly given on: (a) the date of delivery, if delivered in person
against written receipt therefor, or by nationally recognized overnight delivery
service or (b) five (5) days after mailing if mailed from within the continental
United States by postage pre-paid certified mail, return receipt requested to
the party entitled to receive the same:

If to the Company, to:              Thomas Pharmaceuticals, Ltd.
                                    c/o iVoice, Inc.
                                    750 Route 34
                                    Matawan, NJ  07747
                                    Attention:  Jerry Mahoney
                                    Telephone:  (732) 441-7700
                                    Facsimile:  (732) 441-9895

If to the Holder:                   iVoice, Inc.
                                    750 Route 34
                                    Matawan, NJ  07747
                                    Attention:  Jerry Mahoney
                                    Telephone:  (732) 441-7700
                                    Facsimile:  (732) 441-9895

                                        6
<PAGE>

     Section 6.02 Governing Law. This Debenture shall be deemed to be made under
and shall be construed in accordance with the laws of the State of New Jersey
without giving effect to the principals of conflict of laws thereof. Each of the
parties consents to the jurisdiction of the U.S. District Court sitting in the
District of the State of New Jersey or the state courts of the State of New
Jersey sitting in Hudson County, New Jersey in connection with any dispute
arising under this Debenture and hereby waives, to the maximum extent permitted
by law, any objection, including any objection based on forum non conveniens to
the bringing of any such proceeding in such jurisdictions.

     Section 6.03 Severability. The invalidity of any of the provisions of this
Debenture shall not invalidate or otherwise affect any of the other provisions
of this Debenture, which shall remain in full force and effect.

     Section 6.04 Entire Agreement and Amendments. This Debenture represents the
entire agreement between the parties hereto with respect to the subject matter
hereof and there are no representations, warranties or commitments, except as
set forth herein. This Debenture may be amended only by an instrument in writing
executed by the parties hereto.

IN WITNESS WHEREOF, with the intent to be legally bound hereby, the Company as
executed this Debenture as of the date first written above.

                                            THOMAS PHARMACEUTICALS, LTD.

                                            By: _____________________________
                                            Name:
                                            Title:

                                        7
<PAGE>

                                                                  EXECUTION COPY

                                   EXHIBIT "A"

                              NOTICE OF CONVERSION

           (To be executed by the Holder in order to Convert the Note)

TO:

     The undersigned hereby irrevocably elects to convert $ ________________ of
the principal amount of this Debenture into Shares of Common Stock of Thomas
Pharmaceuticals, Inc., according to the conditions stated therein, as of the
Conversion Date written below.

Conversion Date:
Applicable Conversion Price:
Signature:
Name:
Address:
Amount to be converted:  $
Amount of Debenture unconverted: $

Conversion Price per share: $
Number of shares of Common Stock to be
issued:
Please issue the shares of Common Stock
in the following name and to the
following address:
Issue to:
Authorized Signature:
Name:
Title:
Phone Number:
Broker DTC Participant Code:
Account Number:
Address of Receiving Party:
Social Security Number or:
Tax Identification Number of Receiving
Party:

                                       A-1EXHIBIT 10.9
                                                                    ------------

                              EMPLOYMENT AGREEMENT

     AGREEMENT made as of January 6, 2006, by and between Thomas
Pharmaceuticals, Inc., (hereinafter referred to as the "Company"), a New Jersey
corporation, having an office at 750 Highway 34, Matawan, New Jersey 07747 and
John E. Lucas, 1255 North Gulfstream Avenue, Apartment 703, Sarasota, Florida,
34236 (hereinafter referred to as the "Executive").

                              W I T N E S S E T H :

     WHEREAS, the Company desires to engage the services of the Executive, and
the Executive desires to render such services;

     NOW, THEREFORE, in consideration of the premises, the parties agree as
follows:

     1. Employment. The Company hereby employs the Executive as Chief Executive
Officer, and the Executive hereby accepts such employment, subject to the terms
and conditions hereinafter set forth.

     2. Term. The term of the Executive's employment hereunder shall commence on
the date of execution of this Agreement and shall continue to December 31, 2008
(the "Term") unless such Term is earlier terminated in accordance with the
provisions of this Agreement.

     3. Duties. The Executive agrees that the Executive will serve the Company
on a full-time basis faithfully and to the best of his ability as the Chief
Executive Officer of the Company, subject to the general supervision of the
Board of Directors of the Company. The Executive agrees that the Executive will
not, during the term of this Agreement, engage in any other business activity
which interferes with the performance of his obligations under this Agreement
and will devote Executive's entire working time to the business and affairs of
the Company; provided, however, that the foregoing shall not be construed as
precluding the Executive from (i) serving on the board of directors of any
corporation not directly competitive or competitive in any material respect with
the Company, and (ii) investing or trading in securities or other forms of
investment, in each case, so long as such activities do not materially interfere
with the performance of the Executive's duties hereunder and such investments do
not represent the ownership of five percent (5%) or more of the capital stock of
publicly traded entities. Unless otherwise determined by the Company Executive
shall have the title of Chief Executive Officer, and in such capacity shall have
such authority and duties as may be assigned by the Board of Directors.
Performance of Executive's duties hereunder shall in no event require that
Executive relocate to any location outside the New York City metropolitan area.

     4. Compensation.

     (a) In consideration of the services to be rendered by the Executive
hereunder, including, without limitation, any services rendered by the Executive
as director of the Company or of any parent, subsidiary or affiliate of the
Company, the Company agrees to pay the Executive, and the Executive agrees to
accept fixed base compensation (the "Base Salary") at the rate of Sixty Thousand
($60,000), subject to all required federal, state and local payroll deductions,
that shall increase on the anniversary date of January 1, 2007 and upon every
annual anniversary thereafter, at a rate equal to percentage of any increase in
the Consumer Price Index - All Consumers for the New York-Northeastern New
Jersey Region as reported by

<PAGE>

the Bureau of Labor Statistics for the United States, as compared with the same
Consumer Price Index for the immediately preceding year.

     (b) The Executive shall be entitled to 10 days vacation in 2006 and 20 days
vacation during each calendar year thereafter.

     (c) The Executive shall be entitled to such holidays, personal and sick
days in accordance with and subject to the Company's policies for its own senior
executives, as in effect from time to time.

     (d) The Executive shall receive medical benefits via a group health policy
established by the Company. The Company shall pay 100% of the cost of the rate
for a single insured. Should Executive opt for family or other coverage,
Executive will be responsible for paying any incremental cost.

     (e) To the extent that the Executive becomes mentally or physically
disabled, Executive shall continue to receive his salary and other benefits
hereunder until the earlier of expiration of the term of this Agreement or the
termination of this Agreement pursuant to Paragraph 10 hereof; provided,
however, that such salary shall be reduced by any disability benefits Executive
receives from policies maintained and paid for by the Company.

     (f) An annual cash bonus will be paid to the Executive based upon the net
sales of the Company. Such bonus, payable within one hundred and five (105) days
of the end of the Company's fiscal year, shall be equal to 2.5% of net sales in
excess of $1,000,000 in 2006 and 2007, and 4% of net sales over $6 million in
2008.

     5. Business Expenses.

     Executive is authorized to incur, and the Company shall pay and reimburse
him for, all reasonable and necessary business expenses incurred in the
performance of his duties hereunder in accordance with guidelines adopted by the
Board of Directors. The Company will pay and reimburse Employee for all such
reasonable expenses upon the presentation by Employee, from time to time, of an
itemized account of such reasonable expenditures and proper documentation
thereof as evidence that such expenses have been incurred.

     6. Termination by the Company for Cause.

     (a) The Company may terminate Executive's employment hereunder at any time
for Cause by following the procedures required by this Section 6. Termination by
the Company of the Executive's employment for cause (herein referred to as "for
Cause"), shall mean termination upon:

          i.   the willful and continued failure by the Executive to
               substantially perform the Executive's material duties with the
               Company (other than any such failure resulting from the
               Executive's incapacity due to physical or mental illness) after a
               written demand for substantial performance is delivered to the
               Executive by the Board, which demand specifically identifies the
               material duties that the Board believes that the Executive has
               not substantially performed, or

          ii.  the willful engaging by the Executive in conduct that is
               demonstrably and

                                        2
<PAGE>

               materially injurious to the Company, monetarily or otherwise. For
               purposes of this Paragraph 6, no act, or failure to act, on the
               Executive's part, shall be deemed "willful" unless done, or
               omitted to be done, by the Executive not in good faith and
               without reasonable belief that the Executive's action or omission
               was in the best interest of the Company, or the conviction of the
               Executive of a felony (or a plea of guilty or nolo contendre),
               limited solely for a crime related to the business operations of
               the Company, or that results in the Executive being unable to
               substantially carry out his duties as set forth in this
               Agreement, or

          iii. the commission of any act by the Executive against the Company
               that may be construed as the crime of embezzlement, larceny,
               and/or grand larceny.

Any other provision in this paragraph to the contrary notwithstanding, the
Executive shall not be deemed to have been terminated for Termination for Cause
unless and until the Board duly adopts a resolution by the affirmative vote of
no less than two-thirds (2/3) of the entire membership of the Board, at a
meeting of the Board called and held for such purpose (after reasonable notice
to the Executive and an opportunity for the Executive, together with the
Executive's counsel, to be heard before the Board), finding that in the good
faith opinion of the Board, the Executive was guilty of conduct described in
Subparagraphs (i), (ii) or (iii) of this paragraph and specifying the
particulars thereof in detail and a certified copy of such resolution is
delivered to the Executive. Upon a termination of the Executive for Cause, the
Company shall have no further obligations whatsoever to the Executive, and the
Executive will not be entitled to any further payments, compensation or other
benefits from the Company.

     (b) In the event that the Executive's employment is terminated for Cause
pursuant to Section 6(a) hereof, the Company shall pay within thirty (30) days
the following amounts to the Executive:

          i.   any accrued but unpaid Base Salary for services rendered to the
               date of termination;

          ii.  any accrued but unpaid vacation pay; and

          iii. any unpaid expense reimbursement owed to him for periods through
               the date of termination.

     7. Termination by the Company Without Cause. If the Company terminates
Executive's employment other than for Cause pursuant to Section 6 or on account
of death or disability pursuant to Section 9 or 10, the Company shall pay or
provide the Executive with, within thirty (30) days of the date of termination:
(i) any unpaid salary earned under this Agreement prior to the date of
termination; (ii) any accrued but unused vacation prior to the date of
termination; (iii) any unpaid bonus actually earned with respect to the fiscal
year ending on or preceding the date of termination; (iv) a one-time lump sum
payment equal to four week's Base Salary, and (v) any unpaid expense
reimbursement owed to him for periods through the date of termination.

     8. Termination by the Executive. The Executive may terminate his employment
hereunder for "Good Reason," within ninety (90) days of the occurrence of any of
the following events: (i) a material breach of this Agreement by the Company;
(ii) any failure to pay, within a

                                        3
<PAGE>

reasonable amount of time, any part of the Executive's compensation (including
Base Salary and bonus) or to provide the benefits contemplated herein; (iii) any
material reduction or diminution (except temporarily during any period of
physical or mental impairment) in the Executive's titles or primary job
responsibilities with the Company; or (iv) a change in control of the Company.
The Executive shall give the Company written notice of any proposed termination
for Good Reason and the Company shall have thirty (30) days from receipt of such
written notice to cure any ground of termination for Good Reason, as set forth
in this Section. In the event Executive terminates his employment for Good
Reason, he shall not be considered to be in breach of this agreement. In the
event of Termination by Executive for Good Reason, Company shall be obligated to
pay to Executive that compensation due as if Company had terminated Executive
Without Cause pursuant to Section 7 of this Agreement.

     9. Termination Due to Death. In the event of the Executive's death during
the Term of this Agreement, the Executive's employment hereunder shall
immediately and automatically terminate, and the Company shall have no further
obligation or duty to the Executive or his estate or beneficiaries other than
for (a) all earned but unpaid compensation through the date of termination and
(b) any accrued but unpaid vacation pay, other than as required by applicable
law.

     10. Termination Due to Disability. The Company may terminate the
Executive's employment hereunder, upon written notice to the Executive, in the
event that the Executive becomes disabled during the Term through any condition
of either a physical or psychological nature and, as a result is, with
reasonable accommodation, unable to perform the essential functions of the
services contemplated hereunder for a period of one hundred eighty (180) days
during any twelve (12) month period during the Term. Any such termination shall
become effective upon mailing or hand delivery of notice, while the Executive
continues to be unable to perform the essential functions of the services
contemplated hereunder, that the Company has elected to exercise its right to
terminate under this Section 10, and the Company shall have no further
obligation or duty to the Executive other than for all earned but unpaid
compensation through the date of termination, and other than as required by
applicable law. For purposes of determining the Executive's disability, the
existence or nonexistence of a disability shall be conclusively determined by a
physician to be selected by the Executive and the Company in good faith.
Executive shall cooperate in such determination by making himself available.

     11. Non-Disclosure of Confidential Information and Non- Solicitation

     (a) The Executive acknowledges that the Executive has been informed that it
is the policy of the Company to maintain as secret and confidential all
information

          (i)  relating to the products, processes, designs and/or systems used
               by the Company and its Affiliates and

          (ii) relating to the customers and employees of the Company and its
               Affiliates (all such information hereafter referred to as
               "confidential information"), and the Executive further
               acknowledges that such confidential information is of great value
               to the Company.

     For purposes of this Agreement, "Affiliates" means any person or entity or
group of persons or entities acting together that, directly or indirectly,
through one or more intermediaries controls, or is controlled by or is under
common control with the Company.

                                        4
<PAGE>

     The parties recognize that the services to be performed by the Executive
are special and unique, and that by reason of his employment by the Company, the
Executive has and will acquire confidential information as aforesaid. The
parties confirm that it is reasonably necessary to protect the Company's (and
its Affiliates') goodwill, and accordingly the Executive does agree that the
Executive will not directly or indirectly (except where authorized by the Board
of Directors of the Company for the benefit of the Company):

     A. At any time during his employment by the Company or after the Executive
ceases to be employed by the Company, divulge to any persons, firms or
corporations (hereinafter referred to collectively as "third parties"), other
than the Company, its officers, directors, consultants, lawyers, accountants,
agents and representatives, or use or allow or cause or authorize any third
parties to use, any such confidential information; and

     B. At any time during his employment by the Company and for a period of two
(2) years after the Executive ceases to be employed by the Company, solicit or
cause or authorize directly or indirectly to be solicited, for or on behalf of
the Executive or third parties, any business from persons, firms, corporations
or other entities who were at any time within two (2) years prior to the
cessation of his employment hereunder, customers of the Company or its
affiliates with respect to any competing business; and

     C. At any time during his employment by the Company and for a period of two
(2) years after the Executive ceases to be employed by the Company, accept or
cause or authorize directly or indirectly to be accepted, for or on behalf of
the Executive or third parties, any business from any such customers of this
Company or its affiliates with respect to any competing business; and

     D. At any time during his employment by the Company and for a period of two
(2) years after the Executive ceases to be employed by the Company, solicit or
cause or authorize directly or indirectly to be solicited for employment, for or
on behalf of the Executive or third parties, any persons (excluding any
individuals residing in the same immediate primary residence as the Executive,
and/or the Executive's immediate family) who were at any time within one year
prior to the cessation of his employment hereunder, employees of the Company or
its affiliates; and

     E. At any time during his employment by the Company and for a period of two
(2) years after the Executive ceases to be employed by the Company, employ or
cause or authorize directly or indirectly to be employed, for or on behalf of
the Executive or third parties, any such employees of the Company or its
affiliates.

     F. "competing business" shall mean (x) any entity (other than the Company
or any of its affiliates) that then engages, directly or indirectly, in any
business which the Company is then conducting or which is then covered in a
written proposal or business plan in any place in which the Company does
business.

     (b) The Executive agrees that, upon the expiration of his employment by the
Company for any reason, the Executive shall forthwith deliver to the Company any
and all records, drawings, notebooks, keys and other documents and material, and
copies thereof in his possession or under his control which is the property of
the Company or which relate to any confidential information or any discoveries
of the Company.

                                        5
<PAGE>

     (c) The Executive agrees that any breach or threatened breach by the
Executive of any provision of this Section 11 shall entitle the Company, in
addition to any other legal remedies available to it, to enjoin such breach or
threatened breach through any court of competent jurisdiction. The parties
understand and intend that each restriction agreed to by the Executive herein
above shall be construed as separable and divisible from every other
restriction, and that the unenforceability, in whole or in part, of any
restriction will not affect the enforceability of the remaining restrictions,
and that one or more or all of such restrictions may be enforced in whole or in
part as the circumstances warrant.

     (d) For the purposes of this Section, the term "Company" shall mean and
include any and all subsidiaries, parents and affiliated corporations of the
Company in existence from time to time, for which the Company has operational
control.

     12. Successors; Binding Agreement.

     Neither this Agreement nor any right or interest hereunder shall be
assignable by the Executive, nor shall it be subject to attachment, execution,
pledge or hypothecation, but this Agreement if Executive shall die shall inure
to the benefit of and be enforceable by the Executive's personal or legal
representative, executors, administrators, successors, heirs, distributees,
devisees and legatees. If the Executive should die during the term of this
Agreement, except to the extent otherwise provided in Section 9 hereof, no
amounts shall be paid to the Executive's devisee, legatee or other designee or,
if there is no such designee, to the Executive's estate. The rights and
obligations of the Company hereunder will be binding upon and run in favor of
the successors and assigns of the Company who acquire all or substantially all
of the business of the Company.

     13. Miscellaneous. No provision of this Agreement may be modified, waived
or discharged unless such waiver, modification or discharge is agreed to in
writing and signed by the Executive and such officer as may be specifically
designated by the Board. No waiver by either party hereto of, or compliance
with, any condition or provision of this Agreement to be performed by such other
party shall be deemed a waiver of similar or dissimilar provisions or conditions
at the same or at any prior or subsequent time. No agreements or
representations, oral or otherwise, express or implied, with respect to the
subject matter hereof have been made by either party that are not set forth in
this Agreement. Any payments provided for hereunder shall be paid net of any
applicable withholding required under federal, state or local law.

     14. Severance and Validity. The invalidity or unenforceability of any
provision of this Agreement shall not affect the validity or enforceability of
any other provision of this Agreement, which shall remain in full force and
effect.

     15. Counterparts. This Agreement may be executed in several counterparts,
each of which shall be deemed to be an original but all of which together shall
constitute one and the same instrument.

     16. Entire Agreement. This Agreement contains the entire understanding of
the parties with respect to the subject matter hereof, supersedes any prior
agreement between the parties, and may not be changed or terminated orally. No
change, termination or attempted waiver of any of the provisions hereof shall be
binding unless in writing and signed by the party to be bound; provided,
however, that the Executive's compensation and benefits may be increased at any
time by the Company without in any way affecting any of the other terms and
conditions of this Agreement, which in all other respects shall remain in full
force and effect.

                                        6
<PAGE>

     17. Negotiated Agreement. This Agreement has been negotiated and shall not
be construed against the party responsible for drafting all or parts of this
Agreement.

     18. Notices. For the purposes of this Agreement, notices and all other
communications provided for in this Agreement shall be in writing and shall be
deemed to have been duly given when delivered personally, against written
receipt therefrom, or received by United States registered or certified mail,
return receipt requested, postage prepaid, or by nationally recognized overnight
delivery service providing for a signed return receipt, addressed to the
Executive at the Executive's home address set forth in the Company's records and
to the Company at the address set forth on the first page of this Agreement,
provided that all notices to the Company shall be directed to the attention of
the Board with a copy to counsel to the Company, at Kramer Levin Naftalis &
Frankel LLP, 1177 Avenue of the Americas, New York, New York, 10036, Attention:
Scott S. Rosenblum, Esq., or to such other address as either party may have
furnished to the other in writing in accordance herewith, except that notice of
change of address shall be effective only upon receipt.

     19. Governing Law and Resolution of Disputes. All matters concerning the
validity and interpretation of and performance under this Agreement shall be
governed by the laws of the State of New Jersey. Any dispute or controversy
arising under or in connection with this Agreement shall be settled exclusively
by arbitration in Newark, New Jersey in accordance with the rules of the
American Arbitration Association ("AAA") then in effect. Arbitration will take
place before a single experienced employment arbitrator licensed to practice law
in New Jersey and selected in accordance with the Employment Dispute Resolution
Rules of the American Arbitration Association. The arbitrator may not modify or
change this Agreement in any way. Any judgment rendered by the arbitrator as
above provided shall be final and binding on the parties hereto for all purposes
and may be entered in any court having jurisdiction. In any arbitration pursuant
to this Section 19, each party shall be responsible for the fees and expenses of
its own attorney and witnesses, and the fees and expenses of the arbitrator
shall be divided equally between the Company and the Executive. Nothing in this
Section 19 shall be construed to limited the availability of injunctive relief
in the form of a court ordered injunction in connection with an actual or
threatened violation of Section 11 hereof.

                                        7
<PAGE>

     IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of
the date first above written.

JOHN E. LUCAS                          THOMAS PHARMACEUTICALS, INC.

_____________________________          By:___________________________

Date:_________________________         Title:________________________

                                       Date:_________________________

                                        8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00103-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00103-of-00352.parquet"}]]